Bioness has commercially introduced its StimRouter, an implantable neuromodulation device to treat chronic and intractable pain of peripheral nerve origin as an adjunct to other modes of therapy.

In February this year, StimRouter received approval from the US Food and Drug Administration (FDA) to treat chronic pain of peripheral nerve origin.

Bioness president and CEO Todd Cushman said: "The commercial launch of StimRouter for peripheral pain positions Bioness to strategically build on the success of our neuromodulation portfolio.

"In addition to pain applications, we started a pilot study for overactive bladder in February and we anticipate expanding to other commercial markets in the future."

StimRouter is a minimally invasive neuromodulation medical device that features an implanted lead, external pulse transmitter (EPT) and conductive electrode, and is controlled by a small and hand-held wireless control unit.

Electrical signals are said to transmit transdermally from the EPT through the electrode, down the lead to the target nerve.

Bioness produces external and implantable functional electrical stimulation (FES) systems, robotic systems and software-based therapy programs that provide functional and therapeutic benefits for individuals with pain, central nervous system disorders and orthopedic injuries.